AI Analysis AI Analysis of NVO AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add NVO to Watchlist?
Some Reasons Why To Add NVO:
  • High gross margin of 81.8%
  • Strong operating margin of 45.3%
  • Healthy interest coverage ratio of 29.1x
PDF

Novo Nordisk A/S stock downgraded from Buy Candidate to Sell Candidate after Friday trading session
(Updated on Jun 05, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Sell candidate since Jun 05, 2026

The Novo Nordisk A/S stock price fell by -1.81% on the last day (Friday, 5th Jun 2026) from $43.75 to $42.96. During the last trading day the stock fluctuated 3.19% from a day low at $42.86 to a day high of $44.22. The price has been going up and down for this period, and there has been a -3.22% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -14 million shares and in total, 0 shares were bought and sold for approximately $0 .

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $42.31 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 24.89% during the next 3 months and, with a 90% probability hold a price between $52.84 and $61.93 at the end of this 3-month period.

NVO Signals & Forecast

There are few to no technical positive signals at the moment. The Novo Nordisk A/S stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $43.83 and $43.56. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, June 04, 2026, and so far it has fallen -1.81%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Novo Nordisk A/S stock

On the downside, the stock finds support just below today's level from accumulated volume at $38.58 and $37.45. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Novo Nordisk A/S finds support just below today's level at $38.58. If this is broken, then the next support from accumulated volume will be at $37.45 and $36.53.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $1.37 between high and low, or 3.19%. For the last week the stock has had daily average volatility of 3.36%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NVO) For The Upcoming Trading Day Of Monday 8th

For the upcoming trading day on Monday, 8th we expect Novo Nordisk A/S to open at $43.35, and during the day (based on 14 day Average True Range), to move between $42.29 and $43.63, which gives a possible trading interval of +/-$1.33 (+/-3.15%) up or down from last closing price. If Novo Nordisk A/S takes out the full calculated possible swing range there will be an estimated 3.15% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $43.90 (2.19%) than the support at $38.58 (10.20%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Novo Nordisk A/S stock A Buy?

The Novo Nordisk A/S stock holds several negative signals and despite the positive trend, we believe Novo Nordisk A/S will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

Current score: -3.262 Sell Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on June 8, 2026 - $43.35 ( 0.90%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

NVO Performance

Trading levels for NVO

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 44.71 4.07%
R2 44.19 2.86%
R1 43.87 2.11%
Price 42.96
S1 42.82 -0.318%
S2 42.50 -1.07%
S3 41.98 -2.28%

Accumulated Volume Support & Resistance Levels

Level Price
R3 45.76 6.52%
R2 44.39 3.33%
R1 43.90 2.19%
Price 42.96
S1 38.58 -10.20%
S2 37.45 -12.83%
S3 36.53 -14.97%

NVO Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Feb 04, 2026 Mar 30, 2026 Apr 08, 2026 $0.92 1.92%
2 Sep 18, 2025 Sep 18, 2025 Sep 29, 2025 $0.0038 0.0067%
3 Aug 18, 2025 Aug 18, 2025 Aug 26, 2025 $0.412 0.84%
4 Feb 05, 2025 Mar 31, 2025 Apr 08, 2025 $0.787 1.28%
5 Aug 16, 2024 Aug 16, 2024 Aug 26, 2024 $0.374 0.277%

FAQ

What is the symbol for Novo Nordisk A/S Stock and on which exchange is it traded?
The symbol for Novo Nordisk A/S is NVO and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Novo Nordisk A/S Stock?
The Novo Nordisk A/S stock holds several negative signals and despite the positive trend, we believe Novo Nordisk A/S will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.

How to buy Novo Nordisk A/S Stock?
Novo Nordisk A/S Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Novo Nordisk A/S Stock.

What's the current price of Novo Nordisk A/S Stock?
As of the end of day on the Jun 05, 2026, the price of an Novo Nordisk A/S (NVO) share was $42.96.

What is the 52-week high and low for Novo Nordisk A/S Stock?
The 52-week high for Novo Nordisk A/S Stock is $81.44 and the 52-week low is $35.13.

What is the market capitalization of Novo Nordisk A/S Stock?
As of the Jun 05, 2026, the market capitalization of Novo Nordisk A/S is 190.905B.

When is the next earnings date for Novo Nordisk A/S?
The upcoming earnings date for Novo Nordisk A/S is Aug 05, 2026.
Click to get the best stock tips daily for free!
ABOUT NOVO NORDISK A/S
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the ...
GOLDEN STAR
Ticker Change Signal Date
FISV
0% Nov 30
K
KEEL
0% Nov 30
D
DFTX
0% Nov 30
R
RKLZ
0% Nov 30
R
RKTO
0% Nov 30

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE